ClinicalTrials.gg
RecruitingNCT05191680Updated Jun 20, 2025

TherApeutics in Early ProState Cancer (TAPS02)

A Phase 2 interventional study of Apalutamide Oral Tablet [Erleada] and Placebo in Prostate Cancer, sponsored by Cambridge University Hospitals NHS Foundation Trust. Recruiting at 6 sites in United Kingdom. Open to male participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-06-20.

Sponsored by Cambridge University Hospitals NHS Foundation Trust · Phase 2, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Apr 2023; still recruiting 3 years 6 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
90
Allocation
Randomized
Ages
18 Years and older
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 70 studies testing apalutamide in Prostatic Neoplasms — 14 open to participants now, 36 under way, 12 of them phase 3. apalutamide · Prostatic Neoplasms.

Planned enrollment
32nd of 70
90 · median 81
Started
2023
with 4 others
Phase 2
37 of 70
8 open now
Primary completion
2029-10
later than 33 of 35 live
Registered
57th of 70
by date

Among the 70 studies testing apalutamide in Prostatic Neoplasms, this one is the 32nd largest by planned enrollment, is one of 5 that started in 2023, is one of 37 in phase 2, reaches primary completion later than 33 of the 35 other live ones, and was the 57th registered.

Prostatic Neoplasms

7,058 studies on the registry are indexed under Prostatic Neoplasms; 1,582 are open to participants now.

Browse Prostatic Neoplasms studies →

Open to participants now

14 of the 70 studies testing apalutamide in Prostatic Neoplasms are open now, in 11 countries. Recruiting first, the newest first:

8 more — sign in →

By country, each count listing its studies:

All 14 open studies →

About apalutamide

apalutamide: first FDA approval 2018 (ERLEADA), first EMA approval 2019. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,236 Prostatic Neoplasms studies recruiting now, 933 (75%) set no upper age limit and 77 (6%) stop at 75 or younger; 67 take children under 18; 82 take healthy volunteers.

This study: 18 Years and older · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 70 studies testing apalutamide in Prostatic Neoplasms, or all of them as a file.
02

Study summary

This is a phase 2, randomised, multicentre, double-blind, placebo-controlled trial investigating the use of short term androgen deprivation therapy in the form of apalutamide (Erleada) in men on active surveillance for prostate cancer.

03

Conditions studied

  • Prostate Cancer

Browse trials for

Keywords

  • active surveillance
  • prostate cancer
  • therapeutics in prostate cancer
  • apalutamide
  • short term androgen deprivation therapy
  • androgen receptor inhibitor
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

To be included in the trial the patient must:

  • Have given written to participate.
  • Be aged 18 or over.
  • Have an (ECOG) status 0-2.
  • Have selected active surveillance as a management option.
  • Have an MRI detectable lesion with an M score of ≥ 3 using Likert scale OR PI-RADS (version 2.1) reporting criteria. If M score is 3 then lesion size (single or combined) of ≥10mm.
  • Have prostate cancer from a combination of image guided targeted + systematic and MRI lesion and biopsy are concordant for a prostate cancer diagnosis.
  • Not anticipated to require bladder outlet surgery during IMP treatment or for up to 12 months of follow-up.
  • Meet all of the following clinical laboratory assessment criteria:

    • ≥ 9.0 g/dL, independent of transfusion and/or growth factors within 3 months prior to randomisation.
    • count ≥ 100 x 109/L independent of transfusion and/or growth factors within 3 months prior to randomisation.
    • (ANC) ≥ 1.0 x 109/L within 21 days prior to randomisation.
    • Serum albumin ≥ 3.0 g/dL within 21 days prior to randomisation.
    • (GFR) ≥ 30 ml/min AND Serum creatinine ≤ 3 times the (calculated by Cockcroft and Gault equation using actual body weight) within 21 days prior to randomisation.
    • Serum potassium ≥3.5 mmol/L within 21 days prior to randomisation.
    • (AST) or alanine aminotransferase (ALT) ≤2.5 × ULN AND Serum total ≤1.5 × ULN within 21 days prior to randomisation (Note: In patients with confirmed Gilbert's syndrome, if total bilirubin is >1.5 × ULN, measure direct and indirect bilirubin and if direct bilirubin is ≤1.5 × ULN, patient may be eligible in consultation with their physician).
  • Have prostate cancer with any one or more of the following:

    • CPG2 (based on Grade Group 2 on histology)
    • CPG1 (based on Grade Group 1 on histology) with PSA high density (PSAd >0.15) and LIKERT or PI-RADS 4/5 lesion (individual or combined) of ≥10mm size.
    • CPG1 with PSA high density (PSAd >0.15) and ≥50% biopsy core involvement (number of positive cores/all cores taken) with target biopsies counted as one if LIKERT or PI-RADS 3 lesion

Exclusion criteria

EXCLUSION CRITERIA

The presence of any of the following will preclude patient inclusion:

  • to apalutamide or its .
  • Pelvic metalwork interfering with MRI prostate interpretation.
  • Any prior or concurrent use of androgen deprivation therapy (ADT) or androgen receptor targeting agents (not including established and continued use of 5-ARIs for urinary symptoms).
  • Systemic therapy for prostate cancer.
  • Inability for patient to have prostate MRI scan.
  • Concurrent involvement in a Clinical Trial of Medicinal Product (CTIMP); participation in an observational trial/studies is acceptable.
  • Seizure or known condition that may pre-dispose to seizure (including but not limited to the following within 1 year prior to randomisation: prior stroke, , loss of consciousness, brain arteriovenous malformation; or intracranial masses such as schwannomas and meningiomas that are causing oedema or mass effect).
  • Medications known to lower the seizure threshold or cause seizures must be discontinued or substituted at least 28 days prior to randomisation.
  • In the opinion of investigator, patient is at increased risk of falls or fractures.
  • Severe/unstable angina, myocardial infarction, symptomatic congestive heart failure, arterial or venous thromboembolic events (e.g., pulmonary embolism, cerebrovascular accident including transient ischemic attacks), or ventricular arrhythmias within 6 months prior to randomisation. Cardiovascular risk factors should be optimised i.e. hypertension, diabetes, dyslipidaemia.
  • Uncontrolled hypertension (SBP ≥ 160 mmHg or DBP ≥ 90 mmHg). Patients with a history of uncontrolled hypertension are allowed provided blood pressure is controlled by anti-hypertensive treatment.
  • Gastrointestinal disorder affecting absorption.
  • Medicinal products known to prolong the or medicinal products able to induce Torsade de pointes such as class IA (e.g., quinidine, disopyramide) or class III (e.g., amiodarone, sotalol, dofetilide, ibutilide) antiarrhythmic medicinal products, methadone, moxifloxacin, antipsychotics (e.g. haloperidol). Alternative therapy, for the prohibited medication known to prolong the QTc, may be inistigated. A minimum for the discontinued medication of ≥ 4 half-lives is required prior to starting IMP.
  • Symptoms suggestive of Stevens-Johnson syndrome (SJS)/toxic epidermal necrolysis (TEN).
Terms in these criteria, in plain language(17)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
90 participants (estimated)

Study arms

  • Experimental
    Apalutamide 6 months

    Participants will receive apalutamide 240 mg (4 x 60 mg tablets) orally once a day for up to 6 months.

    Drug: Apalutamide Oral Tablet [Erleada]

  • Experimental
    Apalutamide 3 months + Placebo 3 months

    Participants will receive apalutamide 240mg (4 x 60 mg tablets) orally once a day for up to 3 months followed by placebo to match apalutamide (4 tablets) orally once a day for up to 3 months.

    Drug: Apalutamide Oral Tablet [Erleada] · Drug: Placebo

  • Placebo comparator
    Placebo 6 months

    Participants will receive placebo to match apalutamide (4 tablets) orally once a day for up to 6 months.

    Drug: Placebo

Interventions

  • DrugApalutamideStudies of ApalutamideApalutamide pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Apalutamide is a selective Androgen Receptor (AR) inhibitor that binds directly to the ligand-binding domain of the AR.

    Also known as: Erleada

  • DrugPlacebo

    Placebo to match apalutamide

06

What researchers measure

Primary outcomes

  1. MRI defined tumour volume

    To determine whether there is a reduction in MRI defined tumour volume at 12 months post treatment in at least 50% of the treated cohort in either treatment arm compared to the baseline measurement.

    Time frame: 12 months after end of treatment

Secondary outcomes

  1. Reported adverse events

    As per NCI-CTCAE v5.0

    Time frame: Reported from the point of obtaining informed consent until the safety FU visit (30-45 days post-treatment)

  2. Patient-reported outcomes EORTC QLQ-C30

    Assessed using the European Organisation for Research and Treatment of Cancer Quality of Life of Cancer Patients questionnaire (EORTC QLQ-C30).

    Time frame: Cumulative until 12 months after end of treatment

  3. Patient-reported outcomes EQ-5D-5L

    Assessed using the EQ-5D-5L questionnaire developed by the EuroQol Group.

    Time frame: Cumulative until 12 months after end of treatment

  4. Cumulative rate of progression (any progression)

    the overall rate of disease progression

    Time frame: 3 years after completion of treatment

  5. Cumulative rate of progression to any prostate cancer treatment (for any cause)

    the overall rate of conversion to treatment for any causes

    Time frame: 3 years after completion of treatment

07

Study locations

6 of 6 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2023 (actual). Primary completion is estimated for Oct 2029, 78 months after the start.

Of 613 non-industry phase 2 interventional studies under Prostatic Neoplasms, half reached primary completion within 57 months of starting (the median), counting those still running; a quarter within 38 and three quarters within 86. This study's planned 78 months is above that.

Counting every sponsor, half of 727 studies reached it within 53 months; a quarter within 34 and three quarters within 80.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 16, 2021
First posted
Jan 13, 2022
StartActual
Apr 24, 2023
Primary completionEst.
Oct 2029
CompletionEst.
Oct 2029
Last update
Jun 20, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 20, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05191680
Responsible party
Vincent Gnanapragasam (Professor of Urology and Honorary Consultant Urologist, Cambridge University Hospitals NHS Foundation Trust) — Principal investigator
First posted
Jan 13, 2022
Start date
Apr 24, 2023
Primary completion
Oct 2029 (estimated)
Completion
Oct 2029 (estimated)
Last update
Jun 20, 2025

Study contacts

Elizabeth Young
Contact
cuh.taps02trial@nhs.net
01223 256364
Vincent J Gnanapragasam, Prof.
principal investigator · Cambridge University Hospitals NHS Foundation Trust

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Apalutamide

Start the discussion